Thermo Fisher Scientific Releases Q3 2026 Earnings Results

Thermo Fisher Scientific reported 6% organic revenue growth in Q3 2026, driven by strong performance in Pharma Services and Analytical Instruments. The company raised its full-year organic revenue growth guidance to 4% and expects free cash flow of $7-7.5 billion. Management attributed growth to market recovery and AI-driven productivity gains, with plans to reinvest tariff refunds into AI and Pharma Services.

Thermo Fisher Scientific (TMO) reported Q3 2026 earnings with adjusted EPS of $6.68 (vs $6.40 expected) and revenue of $12.14B (vs $11.95B expected). Organic growth was 6%, leading to raised full-year guidance. The stock initially fell 2.5% premarket but recovered to +1.63% intraday. Management expects normal growth by late 2027 or early 2028.

Thermo Fisher Scientific (TMO) reported Q3 revenue growth across most segments, with Life Sciences up 5%, Analytical Instruments up 6%, and Lab Products up 15%. Specialty Diagnostics saw a 6% revenue decline. Adjusted operating margins improved in all segments. The company introduced AI-enabled products and raised its 2026 revenue and EPS guidance to $47.7B-$48.2B and $25.13-$25.43, respectively. It also completed the divestiture of its microbiology business and repaid $1.1B in senior notes.

Thermo Fisher Scientific (TMO) reported Q3 2026 earnings of $6.68 per share, up 15% YoY, and revenues of $12.14B, up 9% YoY, both beating estimates. Despite strong results, TMO stock fell 4.1% in pre-market trading. The company saw growth in most segments except Specialty Diagnostics, which declined 6.5%. Adjusted operating margin widened to 24.5%. TMO also announced strategic partnerships and new product launches. The company plans to provide updated full-year guidance on Oct. 21.

Thermo Fisher Scientific (TMO) reported Q3 2026 earnings of $6.68 per share, beating estimates of $6.40. Revenue grew 9% YoY to $12.14B, exceeding expectations of $11.95B. Operating income rose 15% to $2.97B, with margins improving to 24.5%. Laboratory products and services drove growth, while specialty diagnostics declined. Updated 2026 guidance will be provided.

Thermo Fisher Scientific reported Q3 revenue of $12.14B, up 9% YoY, with adjusted EPS rising 15% to $6.68. Organic growth was 6%, and margins improved. The company launched new products, partnered with Mayo Clinic, and opened new facilities. GAAP EPS increased 9% to $4.64. Shares fell 2% premarket.